Tox issues? Check. Questionable efficacy data? Check. OK to market? ODAC says check that box for Epizyme
Based on the FDA’s own in-house review, Epizyme doesn’t have a whole lot of evidence to prove tazemetostat works well in fighting epithelioid sarcoma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
